OPUS GENETICS INC(NASDAQ:IRD) stock News

IRD Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: CLS VERA RKLB CLYM

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

6 days ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

19 days ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice

20 days ago - By: Opus Genetics, Inc.

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

a month ago - By: Zacks Investment Research - Mentions: SBH BNL

The Under $20 Breakout Trio Investors Shouldn't Ignore

a month ago - By: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Opus Genetics, Inc.

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

2 months ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

2 months ago - By: Zacks Investment Research - Mentions: HQY

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

2 months ago - By: Zacks Investment Research - Mentions: GLUE

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

3 months ago - By: Benzinga - Mentions: VTRS

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

4 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

5 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

5 months ago - By: Zacks Investment Research - Mentions: VTGN

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

5 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

5 months ago - By: Zacks Investment Research - Mentions: BLUE

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Zacks Investment Research - Mentions: HUMA

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

5 months ago - By: Zacks Investment Research - Mentions: PRME

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

6 months ago - By: Zacks Investment Research - Mentions: CUE